The Effects of Continuous Blood Purification for SIRS/MODS Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 3

Mortality.

Study or subgroup	CVVH		Control			Risk ratio	Risk ratio
	Events	Total	Events	Total	Weight	M-H, fixed, 95%Cl	M-H, fixed, 95%Cl
5.1.1.MODS
Sanchez Riera 1997	4	15	7	15	25.2%	0.57 (0.21, 1.55)
Cole et al. 2002 [9]	4	12	4	12	14.4%	1.00 (0.32, 3.10)
Liu et al. 2003 [10]	7	24	12	26	41.5%	0.63 (0.30, 1.34)
Ding and Zhao 2007 [12]	2	11	5	10	18.9%	0.36 (0 09, 1.47)
Subtotal (95%Cl)		62		63	100.0%	0.62 (0.38, 1.01)
Total events	17		28
Heterogeneity: Chi-square = 1.27, df = 3 (𝑃 = 0.74); 𝐼^2 = 0%
Test for overall effect: 𝑍 = 1.91 (𝑃 = 0.06)
5.1.2 SRS
Sander et al. 1997 [6]	9	13	12	13	27.5%	0.75 (0.51, 1.11)
Payen et al. 2009 [16]	20	37	17	39	38.0%	1.24 (0.78, 1.97)
J. Yang and H. Yang 2008 [13]	1	31	6	27	14.7%	0.15 (0.02, 1.13)
Peng et al. 2008 [14]	0	17	2	15	6.1%	0.18 (0.01, 3.43)
Yang et al. 2004 [11]	4	22	5	15	13.7%	0.55 (0.17, 1.70)
Subtotal (95%Cl)		120		109	100.0%	0.78 (0.57, 1.08)
Total events	34		42
Heterogeneity: Chi-square = 7.73, df = 4 (𝑃 = 0.10); 𝐼^2 = 48%
Test for overall effect: 𝑍 = 1.49 (𝑃 = 0.14)
Test for subgroup differences: Chi-square = 0.63, df = 1 (𝑃 = 0.43), 𝐼^2 = 0%